How Ocugen (OCGN) Phase 2 And Phase 3 Milestones Are Reframing The Investment Story [Yahoo! Finance]
Ocugen, Inc. (OCGN)
Company Research
Source: Yahoo! Finance
Ocugen's updated fair value estimate of US$10.36 per share, up from US$9.00, has pushed the price target conversation back into focus for many investors. Analysts linking this change to the latest OCU410 Phase 2 readout and OCU400's progress into Phase 3 are splitting into more bullish and more cautious camps, each with its own view on how these programs fit the updated valuation range that runs from about US$10 to US$22. As you read on, you will see how to follow this evolving narrative and what to watch next in the Ocugen story. Stay updated as the Fair Value for Ocugen shifts by adding it to your watchlist or portfolio . Alternatively, explore our Community to discover new perspectives on Ocugen. What Wall Street Has Been Saying ?? Bullish Takeaways Oppenheimer has started coverage of Ocugen with an Outperform rating and a US$10 price target, reflecting its view that the company is an emerging gene therapy player in blinding ocular disorders, with OCU400 already in Phase 3
Show less
Read more
Impact Snapshot
Event Time:
OCGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OCGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OCGN alerts
High impacting Ocugen, Inc. news events
Weekly update
A roundup of the hottest topics
OCGN
News
- Ocugen spikes as Oppenheimer issues new Outperform on upcoming catalysts [Seeking Alpha]Seeking Alpha
- Oppenheimer Starts Ocugen (OCGN) at Outperform on Gene Therapy Pipeline [Yahoo! Finance]Yahoo! Finance
- Ocugen (OCGN) is now covered by Oppenheimer Holdings, Inc.. They set an "outperform" rating and a $10.00 price target on the stock.MarketBeat
- Ocugen: Downgrading After OCU410 Data Release [Seeking Alpha]Seeking Alpha
- Ocugen (OCGN) had its "buy" rating reaffirmed by Chardan Capital. They now have a $7.00 price target on the stock.MarketBeat
OCGN
Earnings
- 3/4/26 - In-Line
OCGN
Sec Filings
- 3/5/26 - Form 3
- 3/4/26 - Form S-8
- 3/4/26 - Form 10-K
- OCGN's page on the SEC website